Global Bradykinin B1 Receptor Market Size By Type (BI-113823, Others), By Application (Clinic, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Bradykinin B1 Receptor Market was valued at USD 432 million in 2023 and is expected to reach USD 986 million by 2031, growing at a CAGR of 10.7% during the forecast period from 2023 to 2031. Bradykinin B1 receptors are emerging as promising therapeutic targets in the treatment of chronic inflammation, neuropathic pain, and certain cardiovascular and autoimmune disorders. Increased investments in drug discovery, a rise in chronic disease prevalence, and advancements in receptor-targeted therapies are key factors contributing to market expansion.

Drivers:

1. Rising Incidence of Chronic Diseases:

The increasing prevalence of conditions such as rheumatoid arthritis, diabetes-related complications, and chronic inflammation is elevating the demand for targeted therapies, including bradykinin B1 receptor antagonists.

2. Advancements in Receptor-Based Drug Development:

Ongoing innovations in biotechnology and molecular pharmacology are facilitating the discovery of novel compounds that selectively target B1 receptors, offering improved efficacy and reduced side effects.

3. Increased R&D Investment by Pharmaceutical Companies:

Pharma and biotech firms are allocating significant resources toward developing bradykinin B1 receptor-based drugs, especially for diseases with unmet clinical needs.

Restraints:

1. Regulatory Hurdles and Approval Delays:

The complexity of clinical trials and stringent regulatory requirements for novel receptor-targeted therapies can delay product approvals and market entry.

2. Limited Public Awareness and Diagnostic Reach:

In many regions, low awareness about bradykinin-targeted treatment options and lack of diagnostic infrastructure may impede patient access to these therapies.

Opportunity:

1. Expansion into Rare Disease Therapeutics:

Bradykinin B1 receptor antagonists show promise in the treatment of rare and orphan diseases such as hereditary angioedema and interstitial cystitis, presenting lucrative opportunities for niche market players.

2. Personalized Medicine Integration:

The integration of bradykinin B1 receptor modulation with genetic and biomarker-based approaches could pave the way for personalized therapies, enhancing treatment outcomes.

Market by System Type Insights:

Based on system type, the Bradykinin B1 Receptor Antagonists segment accounted for the largest market share in 2023. This dominance is attributed to robust clinical pipelines and the therapeutic potential of these antagonists in inflammatory and neuropathic conditions. The Bradykinin B1 Receptor Agonists segment, though still in the early stages, is expected to witness steady growth due to experimental use in regenerative medicine and controlled inflammation.

Market by End-use Insights:

In terms of end use, the Pharmaceutical and Biotechnology Companies segment led the market in 2023, driven by extensive drug development efforts and clinical trials. The Research Institutions segment is also growing rapidly, supported by government and private funding for receptor biology and novel therapeutic development.

Market by Regional Insights:

North America held the dominant market position in 2023 due to a well-established research ecosystem, advanced healthcare infrastructure, and the presence of leading pharmaceutical companies. Asia-Pacific is expected to exhibit the highest growth during the forecast period, fueled by increasing healthcare investments, supportive regulatory frameworks, and a growing patient population.

Competitive Scenario:

Key players in the Global Bradykinin B1 Receptor Market include Sanofi, Roche, AbbVie, Novartis AG, Merck & Co., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Takeda Pharmaceuticals, and Teva Pharmaceuticals. These companies are actively engaging in collaborative R&D, strategic licensing agreements, and acquisitions to expand their pipeline and market share.

In 2023, AbbVie initiated a Phase II clinical trial for a novel bradykinin B1 receptor antagonist aimed at treating neuropathic pain.

Novartis AG expanded its rare disease therapeutic division in 2024, integrating bradykinin receptor-targeted compounds.

Sanofi partnered with a biotech startup in 2025 to co-develop B1 receptor modulators using AI-based screening tools.

Scope of Work – Global Bradykinin B1 Receptor Market

Key Market Developments:

June 2023: Roche unveiled early results from a Phase I trial showing safety and target engagement for its B1 receptor modulator in chronic pain patients.

October 2024: Merck & Co. filed a patent for a new class of orally bioavailable B1 receptor antagonists.

March 2025: Teva Pharmaceuticals received FDA Fast Track designation for its B1 receptor therapy targeting diabetic neuropathy.

FAQs:

1) What is the current market size of the Global Bradykinin B1 Receptor Market?

The market size was USD 432 million in 2023.

2) What is the major growth driver of the Global Bradykinin B1 Receptor Market?

The primary growth driver is the rising incidence of chronic diseases and related inflammation.

3) Which is the largest region during the forecast period in the Global Bradykinin B1 Receptor Market?

North America is expected to remain the largest regional market.

4) Which segment accounted for the largest market share in the Global Bradykinin B1 Receptor Market?

The Bradykinin B1 Receptor Antagonists segment held the largest share in 2023.

5) Who are the key market players in the Global Bradykinin B1 Receptor Market?

Sanofi, Roche, AbbVie, Novartis AG, Merck & Co., and Eli Lilly and Company are among the leading players.